• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Huh Hoyoung bought 50,000 shares, increasing direct ownership by 0.61% to 8,232,742 units

    9/15/23 4:05:11 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials
    Get the next $IGNY alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Huh Hoyoung

    (Last) (First) (Middle)
    4900 HOPYARD ROAD SUITE 100

    (Street)
    PLEASANTON CA 94588

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Peak Bio, Inc. [ PKBO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    09/13/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 09/13/2023 P 30,000 A (1) 8,212,742 D
    Common Stock 09/14/2023 P 20,000 A (2) 8,232,742 D
    Common Stock 372,940 I See footnote(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. On September 13, 2023, Dr. Hoyoung Huh purchased a total of 30,000 shares of the Company's Common Stock at prices ranging from $0.271 per share to $0.28 per share.
    2. On September 14, 2023, Dr. Hoyoung Huh purchased a total of 20,000 shares of the Company's Common Stock at prices ranging from $0.26 per share to $0.275 per share.
    3. The securities are held by Hannol Ventures LLC. The Reporting Person is sole member of the LLC.
    /s/ Dr. Hoyoung Huh 09/15/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IGNY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IGNY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IGNY
    SEC Filings

    View All

    SEC Form 8-K filed by Ignyte Acquisition Corp.

    8-K - Peak Bio, Inc. (0001834645) (Filer)

    2/6/24 4:09:01 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form 8-K filed by Ignyte Acquisition Corp.

    8-K - Peak Bio, Inc. (0001834645) (Filer)

    1/29/24 5:08:05 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Ignyte Acquisition Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - Peak Bio, Inc. (0001834645) (Filer)

    1/3/24 5:08:00 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lamond Stephen J bought 5,600 shares, increasing direct ownership by 39% to 19,850 units (SEC Form 4)

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:23 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Lamond Stephen J bought 14,250 shares (SEC Form 4) (Amendment)

    4/A - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:04 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4: Huh Hoyoung bought 45,000 shares, increasing direct ownership by 0.54% to 8,382,742 units

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/25/23 4:05:03 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lamond Stephen J bought 5,600 shares, increasing direct ownership by 39% to 19,850 units (SEC Form 4)

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:23 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Lamond Stephen J bought 14,250 shares (SEC Form 4) (Amendment)

    4/A - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:04 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4: Huh Hoyoung bought 45,000 shares, increasing direct ownership by 0.54% to 8,382,742 units

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/25/23 4:05:03 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Financials

    Live finance-specific insights

    View All

    Peak Bio and Ignyte Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Oncology and Inflammation Company

    - Company to be led by Hoyoung Huh, M.D. Ph.D., serial entrepreneur / investor with notable public and private biotech board positions - $25 million private investment in public equity ("PIPE") with participation from leading healthcare institutional investor, Palo Alto Investors (PAI) with additional participation from Peak Bio's CEO, Hoyoung Huh, MD, Ph.D. - Differentiated pipeline includes next generation Neutrophil Elastase Inhibitor targeting AATD / ARDS and robust preclinical ADC oncology platform utilizing Antibody Drug Conjugates - Anticipated cash at closing expected to fully fund the company through 2024 allowing for multiple milestones in ADC program and interim Phase II for A

    4/28/22 4:32:00 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Ignyte Acquisition Corp.

    SC 13D - Peak Bio, Inc. (0001834645) (Subject)

    3/21/23 5:30:30 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G filed by Ignyte Acquisition Corp.

    SC 13G - Peak Bio, Inc. (0001834645) (Subject)

    2/28/23 4:01:06 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G/A filed by Ignyte Acquisition Corp. (Amendment)

    SC 13G/A - Peak Bio, Inc. (0001834645) (Subject)

    2/14/23 3:39:04 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Peak Bio Co., Ltd. to List on NASDAQ Following Successful Business Combination with Ignyte Acquisition Corp.

    Combined Company Scheduled to Commence Trading on NASDAQ Under the Ticker Symbol "PKBO" Peak Bio Co., Ltd. ("Peak Bio"), a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory diseases, today announced the completion of its business combination (the "Business Combination") with Ignyte Acquisition Corp. (NASDAQ:IGNY) ("Ignyte"), a special purpose acquisition company. The transaction was approved at a special meeting of Ignyte's stockholders held on October 25, 2022 (the "Special Meeting"). Ignyte's stockholders also voted to approve all other proposals presented at the Special Meeting. Ignyte's Board of Direct

    11/2/22 7:30:00 AM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Ignyte Acquisition Corp. Stockholders Approve Proposed Business Combination with Peak Bio

    Transaction Expected to Close on October 31, 2022 Ignyte Acquisition Corp. ("Ignyte") (NASDAQ:IGNY), a publicly traded special purpose acquisition company, today announced that Ignyte's stockholders have approved its proposed business combination (the "Business Combination") with Peak Bio Co., Ltd. ("Peak Bio") at a Special Meeting of its stockholders held on October 25, 2022 (the "Special Meeting"). The Special Meeting to be held on October 31, 2022 has been canceled. Approximately 75% of the votes cast at the Special Meeting, representing approximately 75% of Ignyte's outstanding shares of common stock entitled to vote at the Special Meeting, were cast in favor of the proposal to approv

    10/27/22 8:05:00 AM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Peak Bio and Ignyte Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Oncology and Inflammation Company

    - Company to be led by Hoyoung Huh, M.D. Ph.D., serial entrepreneur / investor with notable public and private biotech board positions - $25 million private investment in public equity ("PIPE") with participation from leading healthcare institutional investor, Palo Alto Investors (PAI) with additional participation from Peak Bio's CEO, Hoyoung Huh, MD, Ph.D. - Differentiated pipeline includes next generation Neutrophil Elastase Inhibitor targeting AATD / ARDS and robust preclinical ADC oncology platform utilizing Antibody Drug Conjugates - Anticipated cash at closing expected to fully fund the company through 2024 allowing for multiple milestones in ADC program and interim Phase II for A

    4/28/22 4:32:00 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials